February 17, 2006 – The FDA has given an approvable letter to Acomplia, the much anticipated weight loss drug from Sanofi-Aventis, but Sanofi-Aventis must first meet certain conditions, which remain unknown at the moment; Barrier Therapeutics received FDA approval for Vusion, a topical treatment for diaper rash complicated with yeast infection; GlaxoSmithKline said the FDA accepted its application for Hycamtin for Injection, and has given it priority review status; Alkermes and Cephalon filed their response to an FDA approvable letter for their treatment of alcoholism; the FDA approved an add-on indication for cancer drug Carboplatin Injection from American Pharmaceutical Partners; the FDA is calling for more investigation - but no immediate action - on reports that a birth control patch from Johnson & Johnson increases the risk of blood clots; and Corus Pharma has withdrawn its IPO application, filed in August 2004. The Centient Biotech 200™ gained 5 points to 3973.23, a rise of .13%. More details...
